It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Endothelial dysfunction and vascular smooth muscle cell (VSMC) plasticity are critically involved in the pathogenesis of hypertension and arterial stiffness. MicroRNAs can mediate the cellular communication between vascular endothelial cells (ECs) and neighboring cells. Here, we investigated the role of endothelial-derived extracellular microRNA-92a (miR-92a) in promoting arterial stiffness by regulating EC–VSMC communication. Serum miR-92a level was higher in hypertensive patients than controls. Circulating miR-92a level was positively correlated with pulse wave velocity (PWV), systolic blood pressure (SBP), diastolic blood pressure (DBP), and serum endothelin-1 (ET-1) level, but inversely with serum nitric oxide (NO) level. In vitro, angiotensin II (Ang II)-increased miR-92a level in ECs mediated a contractile-to-synthetic phenotype change of co-cultured VSMCs. In Ang II-infused mice, locked nucleic acid-modified antisense miR-92a (LNA-miR-92a) ameliorated PWV, SBP, DBP, and impaired vasodilation induced by Ang II. LNA-miR-92a administration also reversed the increased levels of proliferative genes and decreased levels of contractile genes induced by Ang II in mouse aortas. Circulating serum miR-92a level and PWV were correlated in these mice. These findings indicate that EC miR-92a may be transported to VSMCs via extracellular vesicles to regulate phenotype changes of VSMCs, leading to arterial stiffness.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 First Affiliated Hospital of Xi’an Jiaotong University, Department of Cardiology, Xi’an, China (GRID:grid.452438.c) (ISNI:0000 0004 1760 8119); Xi’an Jiaotong University Health Science Center, Cardiovascular Research Center, School of Basic Medical Sciences, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)
2 First Affiliated Hospital of Xi’an Jiaotong University, Department of Cardiology, Xi’an, China (GRID:grid.452438.c) (ISNI:0000 0004 1760 8119)
3 Xi’an GaoXin Hospital, Department of Cardiology, Xi’an, China (GRID:grid.43169.39)
4 Xi’an Jiaotong University Health Science Center, Cardiovascular Research Center, School of Basic Medical Sciences, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)
5 Northwestern University, Department of Life Sciences and Medicine, Xi’an, China (GRID:grid.412262.1) (ISNI:0000 0004 1761 5538)
6 Xi’an Chest Hospital, Translational Medicine Centre, Xi’an, China (GRID:grid.508017.b); Xi’an Jiaotong University Health Science Center, Cardiovascular Research Center, School of Basic Medical Sciences, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)
7 University of California, Division of Cardiology, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)